The invention is related to a new method for treating liquid and solid cancers, in a mammal, including human, wherein methioninase is administered before asparaginase. The invention also encompasses the use of a dietary methionine deprivation, possibly combined with methioninase administration, in advance of asparaginase treatment. Methioninase and asparaginase may be used in particular under free form, pegylated form or encapsulated into erythrocytes.

Blood storage and/or rejuvenating compositions that include D-ribose and a nucleoside other than inosine (e.g., guanosine) are disclosed herein. Such compositions can be useful in methods for treating (e.g., storing and/or rejuvenating) red blood cells.

Blood storage and/or rejuvenating compositions that include D-ribose and a nucleoside other than inosine (e.g., guanosine) are disclosed herein. Such compositions can be useful in methods for treating (e.g., storing and/or rejuvenating) red blood cells.

Blood storage and/or rejuvenating compositions that include D-ribose and a nucleoside other than inosine (e.g., guanosine) are disclosed herein. Such compositions can be useful in methods for treating (e.g., storing and/or rejuvenating) red blood cells.

A method for producing erythroid cells comprising culturing erythroid-producer cells which are obtainable from an EMP3-negative individual, and/or have reduced expression of EMP3 and/or reduced expression of one or more downstream effectors of the EMP3 pathway.

A method for producing erythroid cells comprising culturing erythroid-producer cells which are obtainable from an EMP3-negative individual, and/or have reduced expression of EMP3 and/or reduced expression of one or more downstream effectors of the EMP3 pathway.

A population of early-stage burst-forming unit-eryhtoid (BFU-E) cells characterized by low expression of the Type III Transforming Growth Factor β Receptor (TGFRPIII) and uses thereof for producing red blood cells in vitro, genotoxicity analysis of chemicals, drug sensitivity assessment, and drug development. Also described herein are methods for producing the population of early-stage BFU-E cells and methods for producing red blood cells.

A population of early-stage burst-forming unit-eryhtoid (BFU-E) cells characterized by low expression of the Type III Transforming Growth Factor β Receptor (TGFRPIII) and uses thereof for producing red blood cells in vitro, genotoxicity analysis of chemicals, drug sensitivity assessment, and drug development. Also described herein are methods for producing the population of early-stage BFU-E cells and methods for producing red blood cells.

The present invention is related to arginine deiminase encapsulated into erythrocytes for use in therapy. It is in particular related to the use thereof in treating arginase-1 deficiency. Also, it relates to novel pharmaceutical compositions comprising arginine deiminase from M. arginini encapsulated into erythrocytes and the use thereof in treating diseases that may benefit from arginine depletion, such as arginine dependent cancers, in particular arginine-auxotrophic cancers, and arginase-1 deficiency.

The present invention is related to arginine deiminase encapsulated into erythrocytes for use in therapy. It is in particular related to the use thereof in treating arginase-1 deficiency. Also, it relates to novel pharmaceutical compositions comprising arginine deiminase from M. arginini encapsulated into erythrocytes and the use thereof in treating diseases that may benefit from arginine depletion, such as arginine dependent cancers, in particular arginine-auxotrophic cancers, and arginase-1 deficiency.